Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Cantor Fitzgerald
McKesson
McKinsey
Merck
Argus Health
Fuji
Express Scripts
Novartis

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206038

« Back to Dashboard

NDA 206038 describes ORKAMBI, which is a drug marketed by Vertex Pharms Inc and is included in one NDA. It is available from one supplier. There are fifteen patents protecting this drug. Additional details are available on the ORKAMBI profile page.

The generic ingredient in ORKAMBI is ivacaftor; lumacaftor. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ivacaftor; lumacaftor profile page.
Summary for 206038
Tradename:ORKAMBI
Applicant:Vertex Pharms Inc
Ingredient:ivacaftor; lumacaftor
Patents:15
Suppliers and Packaging for NDA: 206038
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038 NDA Vertex Pharmaceuticals Incorporated 51167-700 51167-700-02 4 CARTON in 1 BOX (51167-700-02) > 7 BLISTER PACK in 1 CARTON > 4 TABLET, FILM COATED in 1 BLISTER PACK
ORKAMBI ivacaftor; lumacaftor TABLET;ORAL 206038 NDA Vertex Pharmaceuticals Incorporated 51167-809 51167-809-01 4 CARTON in 1 BOX (51167-809-01) > 7 BLISTER PACK in 1 CARTON > 4 TABLET, FILM COATED in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength125MG;200MG
Approval Date:Jul 2, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 2, 2020
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Jul 2, 2022
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY
Regulatory Exclusivity Expiration:Sep 28, 2023
Regulatory Exclusivity Use:ORPHAN DRUG EXCLUSIVITY

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Boehringer Ingelheim
Federal Trade Commission
UBS
Farmers Insurance
Chinese Patent Office
Julphar
Daiichi Sankyo
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot